Market Overview

BioTime's LifeMap Sciences Launches LifeMap Discovery Version 1.1

Related BTX
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury
BioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE: BTX), announced today the release of LifeMap Discovery^TM version 1.1 (discovery.lifemapsc.com). LifeMap Discovery^TM is a key component in LifeMap's integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards^®, the leading human gene database, and MalaCards, the human disease database. LifeMap Discovery^TM version 1.1 includes significant enhancements of content related to disease targets for stem cell therapy, cells involved in various diseases (such as Parkinson's disease and age related macular degeneration), and a large number of newly added genes relevant to developmental and stem cell biology.

According to Google Analytics, the integrated database suite had more than 13,000,000 page views and more than 2,000,000 unique visitors in the past 12 months. LifeMap clients and partners include dozens of large, fee-paying pharmaceutical and biotechnology companies, as well as leading government patent offices, and its products are used free of charge by scientists at more than a thousand academic institutions worldwide. The integrated database suite also provides a technological foundation for the potential development of additional LifeMap databases and services that will leverage significant and growing web traffic. Moreover, the platform drives life scientists to the LifeMap BioReagents™ portal, which offers cutting-edge stem cell reagents. LifeMap Discovery™ itself is rapidly becoming utilized by researchers and has already reached an audience of 10,000 unique visitors since its launch in November 2012 according to Google Analytics, demonstrating the power of integration between the databases to drive rapid user-base growth across various components of the integrated database suite.

LifeMap Discovery™ is a state-of-the-art roadmap of embryonic development and stem cell biology. The platform integrates embryonic development and stem cell biology with molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. LifeMap Discovery™ is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology and disease mechanisms and etiology. The platform is not only valuable for clinical applications involving stem differentiation and therapies, it will continue to be a key to future product development.

Posted-In: News

 

Related Articles (BTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters